Endo sells international business for $84M
Endo is selling its international pharmaceuticals business to Knight Therapeutics, a Montreal-based specialty pharma company. Endo will get $84 million upfront and could make another $15 million if...
View ArticleMineralys aims to raise $250M; Coherus discloses layoffs
Plus, news about BioNTech, Roche, Boehringer Ingelheim, CervoMed, Genmab, Inozyme Pharma, Valo Therapeutics and Agomab: Mineralys Therapeutics’ $250M follow-on offering: Stellar Phase 3 data for the...
View ArticleWalgreens turns on dark mode
After months of reports that Walgreens was looking to go private, the retail pharmacy giant (to some folks’ surprise) managed to pull off a deal. The $10 billion transaction with ...
View ArticleGilead plans to skip from Phase 1 to Phase 3 with once-yearly PrEP drug
Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage study with a small group of healthy participants. The drugmaker is now planning...
View ArticleMerck dodges ‘failure to warn’ claims in federal Gardasil cases
Merck convinced a federal judge to toss claims alleging that it failed to properly warn patients of potential risks related to its Gardasil HPV vaccine. District Judge Kenneth Bell in North Carolina...
View ArticleFDA review departments largely spared from Musk-led cuts
Since President Trump took office, Elon Musk's Department of Government Efficiency has laid off thousands of government workers through broad, sudden cuts — some later reversed — that have thrown the...
View ArticleUpdated: Zealand partners with Roche on its amylin analog in a deal worth up...
Zealand Pharma has finally found a partner. And according to the Danish company, the licensing deal it announced with Roche on Wednesday for its amylin analog petrelintide is the biggest ever for an...
View ArticleOno licenses rare blood disease drug from Ionis for $280M upfront
Ono Pharmaceutical is spending $280 million upfront to take the global rights of Ionis Pharmaceuticals’ asset for a rare blood disorder, marking the latest partnership for a disease space that has...
View ArticleLegend to double Carvykti production as it targets blockbuster status
Unlocking manufacturing capacity will be key for Legend Biotech and Johnson and Johnson in achieving their goal of reaching “blockbuster status” for Carvykti in 2025, Legend CEO Ying Huang said. The...
View ArticleViking Therapeutics taps CordenPharma to manufacture its obesity drugs
Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss. The Swiss CDMO will...
View ArticleInsilico nabs $110M Series E for AI drug discovery after stalling Hong Kong...
Insilico Medicine, part of the first wave of AI-driven drug discovery and development shops, secured a $110 million megaround at a unicorn valuation for its pipeline of 30 treatment candidates. The...
View ArticleAscletis’ not-so-great weight loss data; Vivace’s $35M Series D
Plus, news about Harbour BioMed: Ascletis’ muscle-preserving drug yields limp weight loss data: The Hong Kong-based biotech said its adipose-targeted obesity therapy, called ASC47, demonstrated...
View Article#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks...
Here are some of the most compelling HIV updates from the annual Conference on Retroviruses and Opportunistic Infections in San Francisco: Merck details Phase 3 wins for two-drug regimen Merck
View ArticleWhy Gilead could lose its HIV product hopping case
Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster predecessor? That's the question before the California Supreme Court, and the...
View ArticleMallinckrodt and Endo exploring a $7B merger — report
Mallinckrodt Pharmaceuticals and Endo are in talks over a potential merger worth about $7 billion, according to a report from Bloomberg News. The outlet reported that the two specialty pharmas are ...
View ArticleUpdated: Endo and Mallinckrodt to merge in $6.7B deal
The rumors are true: Endo will combine with Mallinckrodt in a deal worth $6.7 billion. And the new company, which is yet to be named, will be looking to buy new assets ...
View ArticleAmgen reports more Phase 3 Uplizna data in myasthenia gravis ahead of FDA filing
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s case for label expansion before a planned FDA filing this quarter. The...
View ArticleMontara Therapeutics adds $20M to seed fundraise for neurology pipeline
Montara Therapeutics has raised $20 million in an expanded seed financing to advance a pipeline of preclinical CNS candidates that it says could address safety concerns that have hampered R&D...
View ArticleGoodRx CEO Wendy Barnes on the future of the drug discount company
GoodRx has been in a rut. In its almost five years as a public company, its revenue flatlined, and its stock price plunged about 90%. Its founders stepped down as co-CEOs in 2023, and temporary ...
View ArticleEndpoints wins SABEW award for Health Tech coverage
When Endpoints News launched our Health Tech newsletter in Fall 2023, it was the first time our newsroom had stepped outside the world of biopharma. It was a bet that our readers, and future...
View Article